ivermectin + iota-carrageenan

Ivermectin + iota-carrageenan is a combination therapy consisting of oral ivermectin, an antiparasitic agent with reported antiviral properties, and iota-carrageenan, a sulfated polysaccharide derived from red seaweed used as a nasal spray. This combination has been investigated primarily for the prophylaxis and early intervention of COVID-19 in high-risk populations such as healthcare workers. The proposed mechanism involves a dual barrier to viral infection: iota-carrageenan acts locally in the nasal cavity by forming a physical and possibly mucolytic barrier that impedes viral entry, while ivermectin exerts systemic antiviral effects by reducing viral replication within host cells. Clinical trials have suggested potential synergistic effects in reducing SARS-CoV-2 infection rates among exposed individuals; however, meta-analyses indicate mixed or inconclusive evidence regarding its efficacy for COVID-19 prevention or treatment[1][2][3][4][5].

Other names

IVER/IOTACRC